Congenital Myasthenic Syndrome due to DOK7 mutations in a family from Chile


Submitted: 6 June 2017
Accepted: 16 August 2017
Published: 20 September 2017
Abstract Views: 1577
PDF: 1030
HTML: 214
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

  • Jorge A. Bevilacqua Neuromuscular Unit, Department of Neurology and Neurosurgery, University of Chile Clinical Hospital (HCUCH), Santiago; Program of Anatomy and Developmental Biology, Biomedical Sciences Institute (ICBM), Faculty of Medicine, University of Chile, Santiago, Chile.
  • Marian Lara Department of Neurology, University of California Davis, Davis, CA, United States.
  • Jorge Díaz Department of Radiology, University of Chile Clinical Hospital (HCUCH), Santiago, Chile.
  • Mario Campero Neuromuscular Unit, Department of Neurology and Neurosurgery, University of Chile Clinical Hospital (HCUCH), Santiago, Chile.
  • Jessica Vászquez Department of Neurology, University of California Davis, Davis, CA, United States.
  • Ricardo A. Maselli Department of Neurology, University of California Davis, Davis, CA, United States.
Congenital myasthenic syndromes (CMS) are neuromuscular transmission disorders caused by mutations in genes encoding neuromuscular junction proteins. A 61-year-old female and her older sister showed bilateral ptosis, facial and proximal limb weakness, and scoliosis since childhood. Another female sibling had milder signs, while other family members were asymptomatic. Facial nerve repetitive stimulation in the proband showed decrement of muscle responses. Single fiber EMG revealed increased jitter and blocking. Muscle biopsy showed type 2-fiber atrophy, without tubular aggregates. Mutational analysis in the three affected siblings revealed two compound heterozygous mutations in DOK7: c.1457delC, that predicts p.Pro486Argfs*13 and truncates the protein C-terminal domain, and c.473G>A, that predicts p.Arg158Gln and disruption of the dok7-MuSK interaction in the phosphotyrosine binding (PTB) domain. Unaffected family members carried only one or neither mutation. Discussion. Two of the affected sisters showed marked improvement with salbutamol treatment, which illustrates the benefits of a correct diagnosis and treatment of DOK7-CMS.

Jorge A. Bevilacqua, Neuromuscular Unit, Department of Neurology and Neurosurgery, University of Chile Clinical Hospital (HCUCH), Santiago; Program of Anatomy and Developmental Biology, Biomedical Sciences Institute (ICBM), Faculty of Medicine, University of Chile, Santiago

Full Professor

Dept. Neurology and Neurosurgery, Hospital Clínico Universidad de Chile

Supporting Agencies

NIH, CONICYT, VID Chile

Bevilacqua, J. A., Lara, M., Díaz, J., Campero, M., Vászquez, J., & Maselli, R. A. (2017). Congenital Myasthenic Syndrome due to DOK7 mutations in a family from Chile. European Journal of Translational Myology, 27(3). https://doi.org/10.4081/ejtm.2017.6832

Downloads

Download data is not yet available.

Citations